<DOC>
	<DOCNO>NCT01349725</DOCNO>
	<brief_summary>This Phase 1 study , involve 14-day dosing period , design test safety investigational study drug ARRY-502 healthy subject . Approximately 32 healthy subject United States enrol study .</brief_summary>
	<brief_title>A Safety Study ARRY-502 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Key Healthy male female age 18 50 year . Females must nonchildbearing potential . Body mass index ( BMI ) 18 32 total body weight &gt; 50 kg ( 110 lb ) &lt; 114 kg ( 250 lb ) . Additional criterion exist . Key Evidence history clinically significant disease ( except allergic rhinitis ) . Evidence hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) . Gastrointestinal surgery may interfere motility absorption . Serious illness require hospitalization within previous 6 month . A positive test drug alcohol . Recent use tobacco nicotinecontaining product . Use medication , grapefruit supplement within previous 14 day . Use corticosteroid within previous 28 day . Recent history blood , plasma platelet donation . Treatment smallmolecule investigational drug within previous 30 day biologic therapy within previous 6 month . Prior exposure investigational study drug ARRY502 . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Safety</keyword>
</DOC>